In Washington’s debate over enacting steep funding cuts to Medicaid, words are a central battleground.
Lyell goes all in on CAR-T therapies, buys ImmPACT Bio and trims pipeline
Lyell intends to focus all its resources on CAR T-cell clinical programmes, with LYL119 and PmmPACT’s IMPT-314 being the lead candidates. Image credit: Andrii Yalanskyi